Komboglyze

Metformin Hydrochloride and Saxagliptin, the active ingredient in Komboglyze, is a Biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels. The combination leverages complementary mechanisms to improve glycemic control while minimizing the risk of hypoglycemia.

GNH USA supplies Komboglyze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets.

Komboglyze is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms. - Type 2 diabetes mellitus: improves overall glycemic control and lowers HbA1c levels. - Hyperglycemia associated with insulin resistance: enhances insulin sensitivity and increases glucose‑dependent insulin secretion. - Inadequate response to metformin alone: adds DPP‑4 inhibition to achieve target glucose levels. - Adjunct to lifestyle therapy: supports glucose regulation when diet and exercise are insufficient. - Cardiovascular risk considerations: may provide modest benefit on blood pressure and lipid profile when combined with standard care.

Komboglyze may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial discomfort. - Upper respiratory tract infection: mild cold‑like symptoms. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycemia: especially when combined with other glucose‑lowering agents. - Allergic reactions: rash, angioedema, or anaphylaxis may occur.

When prescribing Komboglyze, clinicians should consider several precautionary measures to ensure patient safety. - Renal function: assess creatinine clearance before initiation and monitor periodically. - Hepatic impairment: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia. - Concomitant sulfonylureas: monitor for hypoglycemia and adjust dose if needed. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Komboglyze can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined with metformin. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase saxagliptin exposure. - Insulin or sulfonylureas: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides): may affect blood glucose control. - Beta‑blockers: can mask hypoglycemia symptoms. - Rifampin: may reduce saxagliptin plasma levels.